Panbela Therapeutics Net Profit Margin 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Panbela Therapeutics net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Panbela Therapeutics net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.6B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$125.3B
Gilead Sciences (GILD)	$103.1B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$97.7B
GSK (GSK)	$89.1B
Alnylam Pharmaceuticals (ALNY)	$34.1B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.3B
Biogen (BIIB)	$28.5B
Moderna (MRNA)	$26.2B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.3B
Genmab (GMAB)	$17.8B
BioMarin Pharmaceutical (BMRN)	$16.1B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
Incyte (INCY)	$12.2B
Exact Sciences (EXAS)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.8B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.2B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Intra-Cellular Therapies (ITCI)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Repligen (RGEN)	$7.8B
Exelixis (EXEL)	$7.5B